Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 3Recruiting 2Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Sarcoma, Ewing 1Melanoma 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × alovudine × 1 year × Clear all
NCT03356470 2026-01-28

Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma

University of Wisconsin, Madison

Completed
5 enrolled
Dermatologic

Melanoma

NCT04067115 2025-12-17

U01CA236220

Sarcoma Alliance for Research through Collaboration

Phase 1/2 Completed
37 enrolled
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡